DU-176b Phase III Clinical Study (Venous Thromboembolism) Randomized Double-Blind Study of DU-176b in Patients Undergoing Total Hip Arthroplasty with Enoxaparin as an Active Control

Status

Unknown

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080220743

Enrollment

600

Registered

2009-06-09

Start date

2009-06-09

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients undergoing total hip arthroplasty

Interventions

investigational material(s) Generic name etc : DU-176b INN of investigational material : edoxaban Therapeutic category code : 333 Anticoagulants Dosage and Administration for Investigational material

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients undergoing unilateral total hip arthroplasty

Exclusion criteria

Exclusion criteria: -Subjects with risks of hemorrhage -Subjects with thromboembolic risks -Subjects who weigh less than 40 kg -Subjects who are pregnant or suspect pregnancy, or subjects who want to become pregnant

Design outcomes

Primary

Measure	Time frame
Proportion of subjects with venous thromboembolism events	—

Secondary

Measure	Time frame
Proportion of subjects with bleeding events	—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026